View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	May 13, 2019
Document And Entity Information
Entity Registrant Name	Medicine Man Technologies, Inc.
Entity Central Index Key	0001622879
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		27,985,098
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 699,979	$ 321,788
Accounts receivable	298,716	1,180,757
Accounts receivable - related party	97,059	125,112
Litigation receivable	1,281,511	1,281,511
Inventory	371,649	489,239
Other assets	213,180	50,824
Total current assets	2,962,094	3,449,231
Non-current assets
Fixed assets, net accumulated depreciation of $131,405 and $82,038	85,948	94,640
Intangible assets, net accumulated amortization of $ and $13,903	85,501	81,197
Goodwill	12,304,306	12,304,306
Investment	1,850,589	2,199,344
Long-term receivable, net of allowance	237,246	92,888
Operating lease right of use assets	238,667	0
Total non-current assets	14,802,257	14,772,375
Total assets	17,764,351	18,221,606
Current liabilities
Accounts payable	660,711	202,515
Accounts payable - related party	0	71,312
Accrued expenses	224,183	291,084
Accrued taxes	711,019	582,931
Other liabilities	582,931	0
Total current liabilities	2,178,844	1,147,842
Long-term liabilities
Lease liabilities	237,384	0
Total long-term liabilities	237,384	0
Total liabilities	2,416,228	1,147,842
Commitments and Contingencies, note 13
Shareholders' equity
Common stock $0.001 par value. 90,000,000 authorized, 28,585,098 and 27,753,310 were issued and outstanding March 31, 2019 and December 31, 2018, respectively.	28,705	27,875
Additional paid-in capital	21,424,510	20,239,163
Additional paid-in capital - Warrants	2,647,461	2,647,461
Retained earnings	(8,752,553)	(5,840,735)
Total Shareholders' equity	15,348,123	17,073,764
Total liabilities and stockholders' equity	$ 17,764,351	$ 18,221,606

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 159,667	$ 149,015
Accumulated amortization	$ 15,599	$ 13,903
Common stock authorized	90,000,000	90,000,000
Common stock par value	$ 0.001	$ 0.001
Common stock issued	28,858,098	27,753,310
Common stock outstanding	28,858,098	27,753,310

Consolidated Statement of Comprehensive (Loss) and Income (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating revenues
Total revenue	$ 2,003,476	$ 1,211,037
Cost of goods and services
Cost of goods and services	1,598,712	373,518
Total cost of goods and services	1,598,712	373,518
Gross profit	404,764	837,519
Operating expenses
General and administrative	295,306	321,921
Professional services	1,901,764	230,517
Salaries	435,721	267,054
Total operating expenses	2,632,791	819,492
Income from operations	(2,228,027)	18,027
Other income/expense
Interest income	0	7,397
Unrealized gain (loss) on derivative liability	(335,036)	0
Unrealized gain/(loss) on investment	(348,755)	0
Total other expense	(683,791)	7,397
Net (loss) income	$ (2,911,818)	$ 25,424
Earnings per share attributable to common shareholders:
Basic and diluted (loss)/earnings per share	$ (0.10)	$ 0.00
Weighted average number of shares outstanding - basic and diluted	27,887,147	24,082,334
Other comprehensive income (loss), net of tax
Net unrealized (loss) on available for sale securities	$ 0	$ 0
Total other comprehensive income (loss), net of tax	0	0
Comprehensive (loss) gain	(2,911,818)	25,424
Product Sales [Member]
Operating revenues
Total revenue	1,383,710	358,044
Product sales - related party [Member]
Operating revenues
Total revenue	160,590	101,291
Consulting and Licensing Services [Member]
Operating revenues
Total revenue	452,380	717,527
Other Operating Revenues [Member]
Operating revenues
Total revenue	$ 3,796	$ 34,175

Statement Of Changes In Stockholders' Equity - USD ($)	Common Stock	Additional Paid-In Capital	Retained Earnings (Loss)	Total
Beginning balance, shares at Dec. 31, 2017	22,991,137
Beginning balance, value at Dec. 31, 2017	$ 23,113	$ 17,505,697	$ (6,789,650)	$ 10,739,160
Issuance of common stock in connection with the exercise of common stock purchase warrants, shares	1,091,197
Issuance of common stock in connection with the exercise of common stock purchase warrants, value	$ 1,091	(1,091)		0
Issuance of common stock in exchange for consulting, professional and other services, value				0
Net income (loss)			25,424	25,424
Ending balance, shares at Mar. 31, 2018	24,082,334
Ending balance, value at Mar. 31, 2018	$ 24,204	17,504,606	(6,764,226)	10,764,584
Beginning balance, shares at Dec. 31, 2018	27,753,310
Beginning balance, value at Dec. 31, 2018	$ 27,875	22,886,624	(5,840,735)	17,073,764
Issuance of common stock in connection with sales made under private or public offerings, shares	118,013
Issuance of common stock in connection with sales made under private or public offerings, value	$ 117	156,839		156,956
Issuance of common stock as compensation to employees, officers and/or directors, shares	550,000
Issuance of common stock as compensation to employees, officers and/or directors, value	$ 550	754,450		755,000
Issuance of common stock in exchange for consulting, professional and other services, shares	163,775
Issuance of common stock in exchange for consulting, professional and other services, value	$ 163	274,058	0	274,221
Net income (loss)			(2,911,818)	(2,911,818)
Ending balance, shares at Mar. 31, 2019	28,585,098
Ending balance, value at Mar. 31, 2019	$ 28,705	$ 24,071,971	$ (8,752,553)	$ 15,348,123

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities
Net income for the period	$ (2,911,818)	$ 25,424
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	12,347	21,220
Common stock issued in exchange for fees and services	755,000	0
Derivative expense	375,983	0
Loss on change in derivative liabilities	335,036	0
Loss on investment, net	348,755	0
Stock based compensation	179,221	0
Changes in operating assets and liabilities
Note receivable	0	(7,397)
Accounts receivable	910,093	(41,173)
Inventory	117,590	(165)
Prepaid expense and other current assets	(67,356)	(41,968)
Operating lease right of use assets and liabilities	(22,613)	0
Accounts payable and other liabilities	341,313	(254,755)
Net cash used from operating activities	373,551	(298,814)
Cash flows from investing activities
Purchase of fixed assets	(1,960)	(9,036)
Purchase of intangible assets	(6,000)	0
Short term debt		(58,280)
Issuance of notes receivable	(144,358)	0
Net cash earned from investing activities	(152,318)	(67,316)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	156,958	0
Net cash earned for financing activities	156,958	0
Net decrease in cash and cash equivalents	378,191	(366,130)
Cash and cash equivalents - beginning of period	321,788	748,715
Cash and cash equivalents - end of period	$ 699,979	$ 382,585

Organization and Nature of Operations

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Description

Organization and Nature of Operations:

Business Description – Business Activity: Medicine Man Technologies Inc. (the "Company") is a Nevada corporation incorporated on March 20, 2014. The Company is a cannabis consulting company providing services related to cost-efficient cannabis cultivation technologies focusing on quality as well as safety, retail operations related to the delivery of cannabis related products, and other related business lines as described in our operating strategic vision outlined below.

1. Liquidity and Capital Resources

3 Months Ended

Mar. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity and Capital Resources

1.	Liquidity and Capital Resources:

Cash Flows – During the quarters ending March 31, 2019 and 2018, the Company primarily used revenues from its operation supplemented by cash to fund its operations.

Cash and cash equivalents are carried at cost and represent cash on hand, deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date. The Company had $699,979 and $321,788 classified as cash and cash equivalents as of March 31, 2019, and December 31, 2018, respectively.

The Company has recently elected to accelerate its organic growth path through additional marketing, team development, synergistic acquisitions, and other corporate activities wherein it expects to generate negative cash flow and an additional demand for capital to fuel such growth.

2. Critical Accounting Policies and Estimates

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Critical Accounting Policies and Estimates

2.	Critical Accounting Policies and Estimates:

Basis of Presentation: These accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for annual financial statements.

Fair Value Measurements: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments include cash, accounts receivable, note receivable, accounts payables and tenant deposits. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of the Company’s debt approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to us. The Company’s derivative liability was adjusted to fair market value at the end of each reporting period, using Level 3 inputs.

The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis at March 31, 2019 and December 31, 2018, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3):

March 31,

2019

December 31,

2018

Level 3 – Non-Marketable Securities – Non-recurring

1,850,589

2,199,344

Non-Marketable Securities at Fair Value on a Nonrecurring Basis: Certain assets are measured at fair value on a nonrecurring basis. The level 3 position consist of investments accounted for under the cost method. The Level 3 position consists of investments in equity securities held in private companies.

Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.

Accounts receivable: The Company extends unsecured credit to its customers in the ordinary course of business. Accounts receivable related to licensing and consulting revenues are recorded at the time the milestone result in the funds being due being achieved, services are delivered, and payment is reasonably assured. Licensing and consulting revenues are generally collected from 30 to 60 days after the invoice is sent. As of March 31, 2019, and December 31, 2018, the Company had accounts receivable of $1,677,287 and $2,587,380, respectively. Due to the low volume of write offs, the Company uses the direct write off method versus having an allowance for uncollectible debts. The Company did not write off any of its accounts receivable in either of the three-month periods ending March 31, 2019 or 2018.

The Company has commenced legal action against a client for breach of contract, adding a significant value into its receivables for fees that had been booked due to forbearance grants by the Company that were subsequent violated, causing the Company to increase its receivables accordingly (see Part II, Item 1, Legal Proceedings). The Company continues to accrue values for fees it would normally be earning during this quarter and as related to the ongoing legal action it initiated after the Client in question refused to pay fees due the Company in accordance with the Client acknowledged executed agreement. At March 31, 2019 and December 31, 2018, the accounts receivable for this matter totaled $1,281,511 and $1,281,511, respectively, and the revenue earned as of December 31, 2018 is $1,518,099. Further, the Company provided services to this Client for a period of thirteen months, agreeing conditionally to three modifications in December of 2017, March of 2018, and May of 2018 to forego certain revenue sharing payments in accordance with the agreement with the Client, which the Client subsequently violated. In July 2018, the Company engaged legal counsel in Clark County Nevada to pursue the default and collect the payments due the Company pursuant to the terms of the agreement with the Client. (See Part II, Item 1, Legal Proceedings).

Notes receivable: On July 17, 2018, the Company entered into an intellectual property license agreement with Abba Medix Corp. (AMC), a wholly-owned subsidiary of a publicly-traded company Canada House Wellness Group, Inc. (CHV). The Company agreed to provide a lending facility to AMC in CAD$125,000 increments of up to CAD$500,000. The lending facilities shall bear an initial interest rate at 5.50% (representing United States Prime) and carry a term of 24 months, unless otherwise amended by both parties.

As of March 31, 2019 and December 31, 2018, the Company loaned to AMC a total of $325,000 CAD or $237,246, and $125,000 CAD or $92,888, respectively. The Company classified these loans as long-term notes receivable on its consolidated balance sheets as of March 31, 2019, and December 31, 2018, respectively.

Other assets (current and non-current): Other assets at March 31, 2019, and December 31, 2018 were $121,456 and $50,824, respectively and as of March 31, 2019 this balance included $102,006 in prepaid expenses and $19,450 in two security deposits.

Accounts payable: Accounts payable at March 31, 2019, and December 31, 2018 was $804,688 and $273,827, respectively and were comprised of operating accounts payable for various professional services incurred during the ordinary course of business.

Accrued expenses and other liabilities: Accrued expenses and other liabilities at March 31, 2019, and December 31, 2018 were $224,183 and $291,084, respectively. At March 31, 2019, this was comprised of customer deposits of $163,568, accrued payroll of $56,669, and operating expenses of $3,946.

At December 31, 2018, this was comprised of $163,568 in customer deposits, $21,330 in deferred rent expense and $106,185 in accrued payroll.

Fair Value of Financial Instruments: The carrying amounts of cash and current assets and liabilities approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. Available for sale securities are recorded at current market value as of the date of this report.

Revenue recognition and related allowances: Our revenue recognition policy is significant because the amount and timing of revenue is a key component of our results of operations. Certain criteria are required to be met in order to recognize revenue. If these criteria are not met, then the associated revenue is deferred until it is met. When consideration is received in advance of the delivery of goods or services, a contract liability is recorded. Our revenue contracts are identified when accepted from customers and represent a single performance obligation to sell our products to a customer.

The Company has five main revenue streams, product sales, licensing and consulting, cultivation max, reimbursements, investment and others.

Revenue from cultivation max, licensing and consulting services is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved.

Product Sales are recorded at the time that control of the products is transferred to customers. In evaluating the timing of the transfer of control of products to customers, we consider several indicators, including significant risks and rewards of products, our right to payment, and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to customers.

Revenue from seminar fees is related to one-day seminars and is recognized as earned at the completion of the seminar. The Company also recognizes expense reimbursement from clients as revenue for expenses incurred during certain jobs.

Costs of Goods and Services Sold – Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of Company’s products and services.

General & Administrative Expenses – General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services.

Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred and were $55,401 and $49,144 during the quarter ended March 31, 2019 and 2018, respectively.

Stock based compensation: The Company accounts for share-based payments pursuant to ASC 718, “Stock Compensation” and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock and restricted stock awards using the Black-Scholes option pricing model.

Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and EITF 96-18 when stock or options are awarded for previous or current service without further recourse. The Company issued stock options to contractors and external companies that had been providing services to the Company upon their termination of services. Under ASC 718 and EITF 96-18 these options were recognized as expense in the period issued because they were given as a form of payment for services already rendered with no recourse.

Share based expense paid to through direct stock grants is expensed as occurred. Since the Company’s stock has become publicly traded, the value is determined based on the number of shares issued and the trading value of the stock on the date of the transaction. Prior to the Company’s stock being traded the Company used the most recent valuation. The Company recognized $1,029,221 in expenses for stock-based compensation to employees and consultants during the three months ended March 31, 2019.

Income taxes: The Company has adopted SFAS No. 109 – “Accounting for Income Taxes”. ASC Topic 740 requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Management fee contracts: In February 2017, the Company entered into a Merger Agreement with Pono Publications Ltd. (“Pono”), as well as a Share Exchange Agreement with Success Nutrients, Inc. (“SN”), each a Colorado corporation, in order to facilitate the acquisition of both of these entities. The ratification of the acquisition of these companies requires the approval of the holders of a majority of the Company’s shareholders, which was submitted for such approval at the Company’s annual shareholder meeting held on May 2017. The relevant agreements provide that the effective date for accounting purposes would be April 1, 2017. Success Nutrients became a wholly owned subsidiary of Medicine Man Technologies, Inc. and the business conducted by Pono was incorporated into a newly formed wholly owned subsidiary, Medicine Man Consulting, Inc., which is also where the Company continues to conduct its consulting service business.

3. Recent Accounting Pronouncements

3 Months Ended

Mar. 31, 2019

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recent Accounting Pronouncements

3.	Recent Accounting Pronouncements

FASB ASU 2016-02 “Leases (Topic 842)” – In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). ASU 2016-02 increases transparency and comparability among organizations by requiring lessees to record right-to-use assets and corresponding lease liabilities on the balance sheet and disclosing key information about lease arrangements. The new guidance will classify leases as either finance or operating (similar to current standard’s “capital” or “operating” classification), with classification affecting the pattern of income recognition in the statement of income. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company has adopted this pronouncement and has reflected the value of all leases within the Balance Sheet of the Company.

FASB ASU 2016-15 “Statement of Cash Flows (Topic 230)” – In August 2016, the FASB issued 2016-15. Stakeholders indicated that there is a diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for annual reporting periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. Adoption of this ASU did not have a significant impact on our statement of cash flows.

FASB ASU 2017-01 “Clarifying the Definition of a Business (Topic 805)” – In January 2017, the FASB issued 2017-1. The new guidance that changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. The guidance requires an entity to evaluate if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. The guidance also requires a business to include at least one substantive process and narrows the definition of outputs by more closely aligning it with how outputs are described in ASC 606. The ASU is effective for annual reporting periods beginning after December 15, 2017, and for interim periods within those years. Adoption of this ASU did not have a significant impact on our consolidated results of operations, cash flows and financial position.

4. Stockholders' Equity

3 Months Ended

Mar. 31, 2019

Equity [Abstract]

Stockholders' Equity

4.	Stockholders’ Equity:

At December 31, 2018, the Company had 27,753,310 shares of common stock outstanding.

On January 2, 2019, the Company issued 82,525 shares of common stock to a vendor in conjunction with services rendered valued at $111,409.

On January 8, 2019, the Company granted to an officer of the Company, Paul Dickman, 500,000 shares of common stock, valued at $660,000.

On February 1, 2019, the Company issued 31,250 shares of common stock to a vendor in conjunction with services rendered valued at $67,812.

On March 14, 2019, the Company granted 50,000 shares of common stock to James Toreson upon his resignation as a member of its board of directors for his service. Additionally, the Company issued 50,000 shares of its common stock to Mr. Toreson in connection with a consulting agreement having a service period extending through May 31, 2020. These shares were valued at $190,000.

At March 31, 2019, the Company had 28,585,098 shares of common stock outstanding.

5. Property and Equipment

3 Months Ended

Mar. 31, 2019

Property, Plant and Equipment [Abstract]

Property and Equipment

5.	Property and Equipment:

Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following:

	March 31, 2019			December 31, 2018
Furniture & Fixtures	$	98,395		$	98,395
Marketing Display		36,900			36,900
Vehicles		34,000			34,000
Office Equipment		76,320			74,361
	$	245,615		$	243,655
Less: Accumulated Depreciation		(159,667	)		(149,015	)
	$	85,948		$	94,640

Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates.

Furniture & Fixtures	3 years
Marketing Display	3 years
Vehicles	3 years
Office Equipment	3 years

Depreciation expense for the three-month periods ending March 31, 2019 and 2018 was $10,651 and $19,591 respectively.

6. Intangible Asset

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Asset

6.	Intangible Asset

On May 1, 2014, the Company entered into a non-exclusive Technology License Agreement with Futurevision, Inc., f/k/a Medicine Man Production Corporation, a Colorado corporation, dba Medicine Man Denver (“Medicine Man Denver”), a company owned and controlled by affiliates of the Company, whereby Medicine Man Denver granted a license to use all of its proprietary processes it has developed, implemented and practiced at its cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical marijuana and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future). As payment for the license rights, the Company issued Medicine Man Denver (or its designees) 5,331,000 shares of the Company’s common stock. The Company accounted for this license in accordance with ASC 350-30-30 “Intangibles – Goodwill and Other by recognizing the fair value of the amount paid by the company for the asset at the time of purchase. Since the Company has a limited operating history, management determined to use par value as the value recognized for the transaction. Since the term of the initial license agreement is ten (10) years, the cost of the asset will be recognized on a straight-line basis over the life of the agreement. In addition, each period the Company will evaluate the intangible asset for impairment. As of March 31, 2019, no impairment was deemed necessary.

During 2017, the Company acquired two intangible assets, Product Agreement & Registration and a Trade Secret. These two intangible assets were acquired as part of the acquisition of Success and Pono on September 30, 2017. Refer to the Note 9 for further explanation of the purchase price accounting. The Company’s procurement of product registration during the year was within five states and Canada. The Company’s product was registered in California, Oregon, Colorado, Michigan, Arizona, Washington and Canada. The registration allows the Company to sell its product within the confines of that region. The registration fees capitalized are the initial costs to obtain the license. The licenses have nominal annual renewal costs. These subscriptions are amortized over a 15-year period.

During 2017, the Company acquired an intangible asset related to the development of a product nutrient recipe. The intellectual property is being amortized over its 15-year economic life. The intangible asset is considered an indefinite lived asset; however, the Company elected to treat it as an amortizable asset based upon its estimated useful life.

During 2017, the Company acquired an additional intangible asset, Product Agreement & Registration. The Company’s procurement of product registration during the year was within seven states. The Company’s product was registered in Florida, Illinois, Maine, Massachusetts, Minnesota, Nevada and Ohio. The registration allows the Company to sell their product within the confines of that region. The registration fees capitalized are the initial costs to obtain the license. The licenses have nominal annual renewal costs. These subscriptions are amortized over a 15-year period.

	March 31, 2019			December 31, 2018
License Agreement	$	5,300		$	5,300
Product License and Registration		63,300			57,300
Trade Secret – IP		32,500			32,500
	$	101,100		$	95,100
Less: accumulated amortization		(15,599	)		(13,903	)
	$	85,501		$	81,197

Amortization expense for the periods ending March 31, 2019 and 2018 was $1,696 and $1,629, respectively.

7. Derivative Liability

3 Months Ended

Mar. 31, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Liability

7.	Derivative Liability:

On January 8, 2019, the Company granted 500,000 shares of restricted common stock to an officer, which will vest upon the achievement of certain market condition milestones. The conditions for vesting require that the Company’s stock price appreciate to $8.00 per share with minimum average daily trading volume thresholds. The Company determined that these vesting conditions represent a derivative instrument. As of March 31, 2019, the fair value of this derivative liability is $711,019.

8. Related Party Transactions

3 Months Ended

Mar. 31, 2019

Related Party Transactions

8.	Related Party Transactions:

During the three months ended March 31, 2019, the Company had sales from Super Farm LLC totaling $190,120 and $51,110 sales from De Best Inc. One of the officers of the Company, Joshua Haupt, currently owns 20% of both De Best and Super Farm. The Company gives a larger discount on nutrient sales to related parties than non-related parties. As of March 31, 2019, the Company had accounts receivable balance with Super Farm LLC totaling $46,780 and $13,660 accounts receivable from De Best Inc. During the three months ended March 31, 2019, the Company had discount of sales associated with Super Farm LLC totaling $94,860 and $25,055 from De Best Inc.

During the three months ended March 31, 2019, the Company had sales from Future Vision dba Medicine Man Denver totaling $71,955 and discount of sales totaling $36,178. As of March 31, 2019, the Company had an accounts receivable balance owed from Future Vision totaling $33,392. As of March 31, 2019, the Company had sales from Med Pharm Holdings totaling $11,995 and discount of sales totaling $7,498. As of March 31, 2019, the Company had an accounts receivable balance owed from Med Pharm Holdings totaling $3,227. Our Chief Executive Officer, Andy Williams, currently owns 38% of Future Vision dba Medicine Man Denver. Andy Williams also owns 10% of Med Pharm Holding.

9. Goodwill and Acquisition Accounting

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Acquisition Accounting

9.	Goodwill and Acquisition accounting:

On June 3, 2017, the Company issued an aggregate of 7,000,000 shares of its common stock for 100% ownership of both Success Nutrients and Pono Publications. The Company accounted for the acquisition utilizing purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in $6,301,080 of Goodwill. The ASC at 350-20-35-3A directs that “An entity may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that the fair value of a reporting unit is less than its carrying amount, including goodwill. The Company had a valuation done at this time and the value exceeded the purchase price indicating that there would not be any impairment.

On July 21, 2017, the Company issued 2,258,065 shares of its Common Stock for 100% ownership of Denver Consulting Group (“DCG”). The Company accounted for the acquisition utilizing purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in $3,003,226 of Goodwill. The ASC at 350-20-35-3A directs that “An entity may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that the fair value of a reporting unit is less than its carrying amount, including goodwill”. The Company obtained an independent valuation of the DCG on September 27, 2017. The fair market value on September 27, 2017 of DCG was $3,650,000, thus creating a fair market value greater than the carrying value of Goodwill. The ASC at 350-20-35-3D directs that “If an entity determines that it is not more likely that the fair value of a reporting unit is less than its carrying amount, then Goodwill impairment is unnecessary.”

On September 17, 2018, we closed the acquisition of Two JS LLC, dba The Big Tomato, a Colorado limited liability company. (“Big T” or “Big Tomato”). The Company issued an aggregate of 1,933,329 shares of its common stock for 100% ownership of Big Tomato. The Company accounted for the transaction utilizing purchase price accounting stating that net book value approximates fair market value of the assets acquired. The purchase price accounting resulted in the Company valuing the investment as $3,000,000 of Goodwill. At September 17, 2018, the Company’s per share value of Common Stock was $1.55. There is no requirement for Big Tomato to have independent audited financial statement for the prior two fiscal years and any interim periods because the aggregate value of the acquisition is less than 20% of the Company’s current assets.

Big Tomato Balance Sheet

	Book/Fair Value		Book/Fair Value
Assets		Liabilities
Inventory	291,000	Accounts payable	272,266
Other assets	4,950	Customer Deposits	23,684
	295,950		295,950

*Purchase Price (1,933,3291.5517)**
	3,000,000
Less: BV of Assets	(295,950	)
Add: BV of Liabilities	295,950
Goodwill	3,000,000

As of March 31, 2019, the Company’s had Goodwill of $12,304,306. This amount consisted of $3,003,226 from the DCG acquisition, $6,301,080 from the Pono and Success acquisition and $3,000,000 from the Big Tomato acquisition. As of March 31, 2019, no impairment is necessary.

10. Net Income (Loss) per Share

3 Months Ended

Mar. 31, 2019

Earnings per share attributable to common shareholders:

Net Income (Loss) per Share

10.	Net Income (Loss) per Share

In accordance with ASC Topic 280 – “Earnings per Share”, the basic earnings per common share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company's quarterly earnings for the period ended March 31, 2019 and 2018 basic and diluted (loss) earnings per share $(0.10) and $0.00, respectively.

11. Inventory

3 Months Ended

Mar. 31, 2019

Inventory Disclosure [Abstract]

Inventory

11.	Inventory:

As of March 31, 2019, and December 31, 2018, respectively, the Company had $371,649 and $489,239 of finished goods inventory. The Company only has finished goods within inventory because it does not produce any of its products. All inventory is produced by a third party. The Company uses the FIFO inventory valuation method. During 2019 and 2018, the Company had $0 obsolescence within its inventory.

12. Note Payable

3 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Note Payable

12.	Note Payable:

As of March 31, 2019, and December 31, 2018, the Company had a note payable balance of $0 and $0, respectively. The Company had a note payable to an officer of the Company, Joshua Haupt. The balance of the note as of December 31, 2017 of $58,280 was repaid in full during the quarter ended March 31, 2018.

13. Leases

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Leases

13.	Leases:

Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. For those leases with a term greater than one year, the Company recognizes on the balance sheet at the time of lease commencement or modification a right of use (“RoU”) operating lease asset and a lease liability, initially measured at the present value of the lease payments. Lease costs are recognized in the income statement over the lease term on a straight-line basis. RoU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease.

The Company's lease population consists of real estate leases for office spaces. The Company elected to combine the lease and related non-lease components for its operating leases.

The Company’s operating leases include options to extend or terminate the lease, which are not included in the determination of the RoU asset or lease liability unless reasonably certain to be exercised. The Company's operating leases have remaining lease terms of less than two years. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

As the Company's leases do not provide an implicit rate, we used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The discount rate used in the computations was 6%.

Balance Sheet Classification of Operating Lease Assets and Liabilities

	Balance Sheet Line	March 31, 2019
Asset
Operating lease asset	Non-Current Assets	$	238,667
Liabilities
Operating lease liability	Non-Current Liabilities	$	237,384

Lease Costs

The table below summarizes the components of lease costs for the three months ended March 31, 2019.

		Three Months Ended March 31, 2019
Operating lease costs		$	39,589

Maturities of Lease Liabilities

Maturities of lease liabilities as of March 31, 2019 are as follows:

2019 fiscal year	$	188,856
2020 fiscal year		67,904
Total lease payments		256,760
Less: Interest		(21,553	)
Present value of lease liabilities	$	235,207

The following table presents the Company’s future minimum lease obligation under ASC 840 as of December 31, 2018:

2019 fiscal year		$	248,808
2020 fiscal year		$	67,904

14. Commitments and Concentrations

3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Concentrations

14.	Commitments and Concentrations:

Over the past three years, the Company has supported legislation in Colorado to allow licensed cannabis companies in Colorado to trade their securities, provided they are reporting companies under the Securities Exchange Act of 1934, as amended. HB19-1090 titled, “Publicly Licensed Marijuana Companies” is currently under consideration in the Colorado legislature. The bill, if signed into law, repeals the provision that prohibits publicly traded corporations from holding a marijuana license in Colorado. Should this legislation be adopted we intend to acquire cannabis licensed companies within Colorado.

The Company has executed binding term sheets with three entities for potential acquisitions and has issued common stock purchase warrants to each to become effective for execution in the event that such legislation passes. The term sheets provide for the issuance of shares of common stock to the targets at an initial price per share of $1.32, with the final price to be determined based on the fair market valuation, which is subject to an independent valuation assessment. The shares will be issued as part of the consideration to the acquisition targets, which acquisitions are subject to certain closing conditions.

Our Chief Executive Officer, Andrew Williams, serves as an officer/manager and has an ownership interest in each of the targets that are parties to the binding term sheets.

15. Warrants

3 Months Ended

Mar. 31, 2019

Equity [Abstract]

Warrants

15.	Warrants:

The Company issued one round of warrants related to various equity transactions that was approved by the Board on June 3, 2017 and issued on June 19, 2017. Since the terms were not established until June 19, 2017, the warrants were valued as of the date the terms were fixed. The Company accounts for its warrants issued in accordance with the US GAAP accounting guidance under ASC 480. The Company estimated the fair value of these warrants at the respective balance sheet dates using the Black-Scholes option pricing model, as described in the stock-based compensation paragraph of Note 2 above, based on the estimated market value of the underlying common stock at the valuation measurement date of $1.50, the remaining contractual term of the warrant of 2.5 years, risk-free interest rate of 1.38% and expected volatility of the price of the underlying common stock of 126%. There is a moderate degree of subjectivity involved when using option pricing models to estimate the warrants and the assumptions used in the Black Scholes option-pricing model are moderately judgmental.

During the year ended December 31, 2017, the Company issued 1,500,566 common stock purchase warrants with an exercise price of $1.33 per share, expiring on March 17, 2019. As of December 31, 2017, none of the warrants were exercised. The common stock purchase warrants have been accounted for as equity in accordance with FASB ASC 480, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity.

During the period ended December 31, 2017, the Company issued 2,000,000 common stock purchase warrants to three employees of the Company with an exercise price of $1.445 per share, expiring on December 31, 2019. As of March 31, 2018, all these warrants were exercised.

During the year ended December 31, 2018, the Company issued 250,000 common stock purchase warrants to one employee of the Company with an exercise price of $1.49 per share for a period of time expiring on December 31, 2021. The Company accounts for the warrant in accordance with the US GAAP accounting guidance under ASC 480. We estimated the fair value of these warrants at the respective balance sheet dates using the Black-Scholes option pricing model based on the estimated market value of the underlying common stock at the valuation measurement date of $1.49, the remaining contractual term of the warrant of 3 years, risk-free interest rate of 2.48% and expected volatility of the price of the underlying common stock of 126%. There is a moderate degree of subjectivity involved when using option pricing models to estimate the warrants and the assumptions used in the Black Scholes option-pricing model are moderately judgmental.

	Number of shares
Balance as of January 1, 2019		2,647,461
Warrants forfeited		(1,500,566	)
Balance as of March 31, 2019		1,146,895

16. Segment Information

3 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Segment Information

16.	Segment Information:

The Company has two identifiable segments as of March 31, 2019; licensing/consulting and products. The products segment sells merchandise directly to customers via e-commerce portals, through our proprietary websites and retail location. The licensing/consulting segment sales derives its revenue from licensing/consulting agreements with cannabis related entities. The following information represents segment activity for the three-month periods ended March 31, 2019 and 2018.

	For the Three Months Ended March 31,
	2019									2018
	Products			Licensing and Consulting			Total			Products			Licensing and Consulting		Total
Revenues	$	1,578,307		$	425,169		$	2,003,476		$	459,335		$	751,702	$	1,211,037
Intangible assets amortization	$	1,563		$	133		$	1,696		$	1,496		$	133	$	1,629
Depreciation	$	1,700		$	8,951		$	10,651		$	1,700		$	17,891	$	19,591
Income (loss) from operations	$	(137,905	)	$	(2,871,881	)	$	(3,009,786	)	$	(71,561	)	$	89,588	$	18,027
Segment assets	$	5,212,682		$	12,551,669		$	17,764,351		$	566,681		$	10,820,260	$	11,386,941

17. Tax Provision

3 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Tax Provision

17.	Tax Provision:

The company utilizes FASB ASC 740, “Income Taxes” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the tax basis of assets and liabilities and their financial reporting amounts based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established if it is more likely than not that some portion or all of the deferred tax asset will not be realized. The Company generated a deferred tax credit through net operating loss carry forwards. The Company had no tax provisions as of March 31, 2019 and December 31, 2018. The company had a net loss during the quarter ended March 31, 2019, increased the net loss carryforward.

18. Subsequent Events

3 Months Ended

Mar. 31, 2019

Subsequent Events [Abstract]

Subsequent Events

18.	Subsequent events:

In accordance with FASB ASC 855-10 Subsequent Events, the Company has analyzed its operations subsequent to March 31, 2019 to the date these consolidated financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these consolidated financial statements.

2. Critical Accounting Policies and Estimates (Policies)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation

Fair Value Measurements

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities.

March 31,

2019

December 31,

2018

Level 3 – Non-Marketable Securities – Non-recurring

1,850,589

2,199,344

Use of Estimates

Accounts receivable

Notes receivable

Other assets (current and non-current)

Accounts payable

Accrued expenses and other liabilities

At December 31, 2018, this was comprised of $163,568 in customer deposits, $21,330 in deferred rent expense and $106,185 in accrued payroll.

Fair Value of Financial Instruments

Revenue recognition and related allowances

The Company has five main revenue streams, product sales, licensing and consulting, cultivation max, reimbursements, investment and others.

Revenue from cultivation max, licensing and consulting services is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved.

Cost of Goods and Services Sold

Costs of Goods and Services Sold – Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of Company’s products and services.

General and Administrative Expenses

General & Administrative Expenses – General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services.

Advertising and Marketing Costs

Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred and were $55,401 and $49,144 during the quarter ended March 31, 2019 and 2018, respectively.

Stock-based compensation

Income taxes

Management fee contracts

2. Critical Accounting Policies and Estimates (Table)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Schedule of fair value measurement

March 31,

2019

December 31,

2018

Level 3 – Non-Marketable Securities – Non-recurring

1,850,589

2,199,344

5. Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2019

Property, Plant and Equipment [Abstract]

Property and equipment table

	March 31, 2019			December 31, 2018
Furniture & Fixtures	$	98,395		$	98,395
Marketing Display		36,900			36,900
Vehicles		34,000			34,000
Office Equipment		76,320			74,361
	$	245,615		$	243,655
Less: Accumulated Depreciation		(159,667	)		(149,015	)
	$	85,948		$	94,640

Schedule of property and equipment useful lives

Furniture & Fixtures	3 years
Marketing Display	3 years
Vehicles	3 years
Office Equipment	3 years

6. Intangible Asset (Tables)

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

License Agreement

	March 31, 2019			December 31, 2018
License Agreement	$	5,300		$	5,300
Product License and Registration		63,300			57,300
Trade Secret – IP		32,500			32,500
	$	101,100		$	95,100
Less: accumulated amortization		(15,599	)		(13,903	)
	$	85,501		$	81,197

9. Goodwill and Acquisition Accounting (Tables)

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Acquisition value

Big Tomato Balance Sheet

	Book/Fair Value		Book/Fair Value
Assets		Liabilities
Inventory	291,000	Accounts payable	272,266
Other assets	4,950	Customer Deposits	23,684
	295,950		295,950

*Purchase Price (1,933,3291.5517)**
	3,000,000
Less: BV of Assets	(295,950	)
Add: BV of Liabilities	295,950
Goodwill	3,000,000

13. Leases (Tables)

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Balance Sheet Classification Table

	Balance Sheet Line	March 31, 2019
Asset
Operating lease asset	Non-Current Assets	$	238,667
Liabilities
Operating lease liability	Non-Current Liabilities	$	237,384

Operating Lease Costs

		Three Months Ended March 31, 2019
Operating lease costs		$	39,589

Maturities of Lease Liabilities

2019 fiscal year	$	188,856
2020 fiscal year		67,904
Total lease payments		256,760
Less: Interest		(21,553	)
Present value of lease liabilities	$	235,207

Future minimum lease obligations

2019 fiscal year		$	248,808
2020 fiscal year		$	67,904

15. Warrants (Tables)

3 Months Ended

Mar. 31, 2019

Equity [Abstract]

Schedule of warrant activity

	Number of shares
Balance as of January 1, 2019		2,647,461
Warrants forfeited		(1,500,566	)
Balance as of March 31, 2019		1,146,895

16. Segment Information (Tables)

3 Months Ended

Mar. 31, 2019

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

	For the Three Months Ended March 31,
	2019									2018
	Products			Licensing and Consulting			Total			Products			Licensing and Consulting		Total
Revenues	$	1,578,307		$	425,169		$	2,003,476		$	459,335		$	751,702	$	1,211,037
Intangible assets amortization	$	1,563		$	133		$	1,696		$	1,496		$	133	$	1,629
Depreciation	$	1,700		$	8,951		$	10,651		$	1,700		$	17,891	$	19,591
Income (loss) from operations	$	(137,905	)	$	(2,871,881	)	$	(3,009,786	)	$	(71,561	)	$	89,588	$	18,027
Segment assets	$	5,212,682		$	12,551,669		$	17,764,351		$	566,681		$	10,820,260	$	11,386,941

1. Liquidity and Capital Resources (Details Narrative) - USD ($)	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 699,979	$ 321,788	$ 382,585	$ 748,715

2. Critical Accounting Policies and Estimates (Details - Level 3) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Fair Value Inputs Level 3 [Member] \| Fair Value Measurements Nonrecurring [Member] \| Non-Marketable Securities [Member]
Fair value assets	$ 1,850,589	$ 2,199,344

2. Critical Accounting Policies and Estimates (Details Narrative)	3 Months Ended		12 Months Ended
	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)	Mar. 31, 2019 CAD ($)	Dec. 31, 2018 CAD ($)
Accounts receivable	$ 1,677,287		$ 2,587,380
Revenues	2,003,476	$ 1,211,037
Accounts receivable written off	0	0
Litigation receivable	1,281,511		1,281,511
Long-term notes receivable	237,246		92,888
Other assets	121,456		50,824
Accounts payable	804,688		273,827
Accrued expenses and other liabilities	224,183		291,084
Advertising and marketing expense	55,401	49,144
Stock based compensation expense	179,221	$ 0
AMC [Member] \| C A D [Member]
Long-term notes receivable				$ 325,000	$ 125,000
Client Litigation [Member]
Revenues			1,518,099
Prepaid Expenses [Member]
Other assets	102,006
Security Deposits [Member]
Other assets	19,450
Customer Deposits [Member]
Accrued expenses and other liabilities	163,568		163,568
Accrued Payroll [Member]
Accrued expenses and other liabilities	56,669		106,185
Operating Expenses [Member]
Accrued expenses and other liabilities	$ 3,946
Deferred Rent Expense [Member]
Accrued expenses and other liabilities			$ 21,330

4. Stockholders' Equity (Details Narrative) - USD ($)			1 Months Ended	2 Months Ended	3 Months Ended
4. Stockholders' Equity (Details Narrative) - USD ($)	Jan. 08, 2019	Jan. 02, 2019	Feb. 01, 2019	Mar. 14, 2019	Mar. 31, 2019	Mar. 31, 2018
Stock issued for services, value					$ 274,221	$ 0
Stock issued for compensation, value					$ 755,000
Paul Dickman [Member]
Restricted stock granted, shares	500,000
Vendor [Member]
Stock issued for services, shares		82,525	31,250
Stock issued for services, value		$ 111,409	$ 67,812
James Toreson [Member]
Stock issued for services, shares				50,000
Stock issued for compensation, shares				50,000
Stock issued for compensation, value				$ 190,000

5. Property and Equipment (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Property and Equipment, gross	$ 245,615	$ 243,655
Less: Accumulated Depreciation	(159,667)	(149,015)
Property and equipment, net	85,948	94,640
Furniture and Fixtures [Member]
Property and Equipment, gross	98,395	98,395
Marketing Display [Member]
Property and Equipment, gross	36,900	36,900
Vehicles [Member]
Property and Equipment, gross	34,000	34,000
Office Equipment [Member]
Property and Equipment, gross	$ 76,320	$ 74,361

5. Property and Equipment (Details - Expected life)	3 Months Ended
5. Property and Equipment (Details - Expected life)	Mar. 31, 2019
Furniture and Fixtures [Member]
Estimated useful life	3 years
Marketing Display [Member]
Estimated useful life	3 years
Vehicles [Member]
Estimated useful life	3 years
Office Equipment [Member]
Estimated useful life	3 years

5. Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
5. Property and Equipment (Details Narrative) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 10,651	$ 19,591

6. Intangible Asset (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Intangible assets, gross	$ 101,100	$ 95,100
Less: accumulated amortization	(15,599)	(13,903)
Intangible assets, net	85,501	81,197
License Agreement [Member]
Intangible assets, gross	5,300	5,300
Product License and Registration [Member]
Intangible assets, gross	63,300	57,300
Trade Secret [Member]
Intangible assets, gross	$ 32,500	$ 32,500

6. Intangible Asset (Details Narrative) - USD ($)	3 Months Ended
6. Intangible Asset (Details Narrative) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 1,696	$ 1,629

7. Derivative Liability (Details Narrative)	Mar. 31, 2019 USD ($)
Debt Disclosure [Abstract]
Derivative liability	$ 711,019

8. Related Party Transactions (Details Narrative)	3 Months Ended
8. Related Party Transactions (Details Narrative)	Mar. 31, 2019 USD ($)
Super Farm LLC [Member]
Revenue from related parties	$ 190,120
Accounts receivable from related parties	46,780
Discount on sales given	94,860
De Best [Member]
Revenue from related parties	51,100
Accounts receivable from related parties	13,660
Discount on sales given	25,055
Medicine Man Denver [Member]
Revenue from related parties	71,955
Accounts receivable from related parties	33,392
Discount on sales given	36,178
Med Pharm Holdings [Member]
Revenue from related parties	11,995
Accounts receivable from related parties	3,227
Discount on sales given	$ 7,498

9. Goodwill and Acquisition Accounting (Details) - USD ($)	9 Months Ended
	Sep. 17, 2018	Mar. 31, 2019	Dec. 31, 2018
Business Combination assumed assets/liabilities
Goodwill		$ 12,304,306	$ 12,304,306
Big Tomato [Member]
Business Combination assumed assets/liabilities
Inventory	$ 291,000
Other assets	4,950
Total assets	295,950
Accounts payable	272,266
Customer deposits	23,684
Total liabilities	295,950
Purchase price	3,000,000
Less: Book value of assets	(295,950)
Add: Book value of liabilities	295,950
Goodwill	$ 3,000,000	$ 3,000,000

9. Goodwill and Acquisition Accounting (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 17, 2018
Goodwill	$ 12,304,306	$ 12,304,306
Impairment	0
Denver Consulting Group [Member]
Goodwill	3,003,226
Success Nutrients and Pono Publications [Member]
Goodwill	6,301,080
Big Tomato [Member]
Goodwill	$ 3,000,000		$ 3,000,000

10. Net Income (Loss) per Share (Details Narrative) - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Earnings per share attributable to common shareholders:
Basic and diluted earnings/(loss) per share	$ (0.10)	$ 0.00

11. Inventory (Details Narrative) - USD ($)	3 Months Ended
11. Inventory (Details Narrative) - USD ($)	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Inventory Disclosure [Abstract]
Finished goods inventory	$ 371,649		$ 489,239
Inventory obsolescence	$ 0	$ 0

12. Note Payable (Details Narrative) - Josh Haupt [Member] - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2019	Dec. 31, 2018
Note payable		$ 0	$ 58,280
Repayments of note payable	$ 58,280

13. Leases (Details - Balance Sheet Classification) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Operating lease asset - non-current	$ 238,667	$ 0
Operating lease liability - non-current	$ 237,384	$ 0

13. Leases (Details - Operating lease cost)	3 Months Ended
13. Leases (Details - Operating lease cost)	Mar. 31, 2019 USD ($)
Leases [Abstract]
Operating lease costs	$ 39,589

13. Leases (Details - Lease maturities)	Mar. 31, 2019 USD ($)
Leases [Abstract]
2019 fiscal year	$ 188,856
2020 fiscal year	67,904
Total lease payments	256,760
Less: interest	(21,553)
Present value of lease liabilities	$ 235,207

13. Leases (Details - Minimum lease obligation)	Mar. 31, 2019 USD ($)
Leases [Abstract]
2019 fiscal year	$ 248,808
2020 fiscal year	$ 67,904

13. Leases (Details Narrative)	Mar. 31, 2019
Leases [Abstract]
Weighted average remaining lease term	2 years
Weighted average lease discount rate	6.00%

15. Warrants (Details) - Warrants [Member]	3 Months Ended
15. Warrants (Details) - Warrants [Member]	Mar. 31, 2019 shares
Warrants outstanding, beginning balance	2,647,461
Warrants forfeited	(1,500,566)
Warrants outstanding, ending balance	1,146,895

15. Warrants (Details Narrative) - Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Issued 2017 [Member]
Warrants issued		1,500,566
Warrant exercise price		$ 1.33
Warrant expiration date		Mar. 17, 2019
Warrants exercised		0
Three Employees [Member]
Warrants issued		1,000,000
Warrant exercise price		$ 1.445
Warrant expiration date		Dec. 31, 2019
Warrants exercised		1,000,000
One Employee [Member]
Warrants issued	250,000
Warrant exercise price	$ 1.49
Warrant expiration date	Dec. 31, 2021

16. Segment Information (Details- Segment Information) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Revenues	$ 2,003,476	$ 1,211,037
Intangible assets amortization	1,696	1,629
Depreciation	10,651	19,591
Income (loss) from operations	(2,228,027)	18,027
Segment assets	17,764,351	11,386,941	$ 18,221,606
Products [Member]
Revenues	1,578,307	459,335
Intangible assets amortization	1,563	1,496
Depreciation	1,700	1,700
Income (loss) from operations	(137,905)	(71,561)
Segment assets	5,212,682	566,681
Licensing/Consulting [Member]
Revenues	425,169	751,702
Intangible assets amortization	133	133
Depreciation	8,951	17,891
Income (loss) from operations	(2,871,881)	89,588
Segment assets	$ 12,551,669	$ 10,820,260